Cyclacel Pharmaceuticals (CYCC +40.4%) soars after saying that Phase II studies of it's lead drug candidate Sapacitabine, a treatment for older patients with intermediate-2 or high-risk myelodysplastic syndrome, nearly doubled expected survival rates for elderly patients.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs